Cargando…
Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2
COVID-19 is a global health emergency that causes serious concerns. A global effort is underway to identify drugs for the treatment of COVID-19. One possible solution to the present problem is to develop drugs that can inhibit SARS-CoV-2 main protease (M(pro)), a coronavirus protein that been consid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537974/ https://www.ncbi.nlm.nih.gov/pubmed/34720187 http://dx.doi.org/10.1016/j.lwt.2021.112684 |
_version_ | 1784588396599967744 |
---|---|
author | Zhao, Wenzhu Li, Xin Yu, Zhipeng Wu, Sijia Ding, Long Liu, Jingbo |
author_facet | Zhao, Wenzhu Li, Xin Yu, Zhipeng Wu, Sijia Ding, Long Liu, Jingbo |
author_sort | Zhao, Wenzhu |
collection | PubMed |
description | COVID-19 is a global health emergency that causes serious concerns. A global effort is underway to identify drugs for the treatment of COVID-19. One possible solution to the present problem is to develop drugs that can inhibit SARS-CoV-2 main protease (M(pro)), a coronavirus protein that been considered as one among many drug targets. In this work, lactoferrin from Bos taurus L. was in silico hydrolyzed. The bioactivity, water solubility, and ADMET properties of the generated peptides were predicted using various online tools. The molecular interactions between M(pro) and the peptides were studied using molecular docking and molecular dynamic simulation. The results demonstrated that peptide GSRY was predicted to have better physicochemical properties, and the value of ‘-C DOCKER interaction energy’ between peptide GSRY and M(pro) was 80.8505 kcal/mol. The interaction between the peptide GSRY and the native ligand N3 co-crystallized with M(pro) had overlapped amino acids, i.e., HIS163, GlY143, GLU166, GLN189 and MET165. Molecular dynamic simulation revealed that M(pro)/GSRY complexes were stable. Collectively, the peptide GSRY may be a potential candidate drug against M(pro) of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8537974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85379742021-10-25 Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 Zhao, Wenzhu Li, Xin Yu, Zhipeng Wu, Sijia Ding, Long Liu, Jingbo Lebensm Wiss Technol Article COVID-19 is a global health emergency that causes serious concerns. A global effort is underway to identify drugs for the treatment of COVID-19. One possible solution to the present problem is to develop drugs that can inhibit SARS-CoV-2 main protease (M(pro)), a coronavirus protein that been considered as one among many drug targets. In this work, lactoferrin from Bos taurus L. was in silico hydrolyzed. The bioactivity, water solubility, and ADMET properties of the generated peptides were predicted using various online tools. The molecular interactions between M(pro) and the peptides were studied using molecular docking and molecular dynamic simulation. The results demonstrated that peptide GSRY was predicted to have better physicochemical properties, and the value of ‘-C DOCKER interaction energy’ between peptide GSRY and M(pro) was 80.8505 kcal/mol. The interaction between the peptide GSRY and the native ligand N3 co-crystallized with M(pro) had overlapped amino acids, i.e., HIS163, GlY143, GLU166, GLN189 and MET165. Molecular dynamic simulation revealed that M(pro)/GSRY complexes were stable. Collectively, the peptide GSRY may be a potential candidate drug against M(pro) of SARS-CoV-2. The Authors. Published by Elsevier Ltd. 2022-01-15 2021-10-23 /pmc/articles/PMC8537974/ /pubmed/34720187 http://dx.doi.org/10.1016/j.lwt.2021.112684 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zhao, Wenzhu Li, Xin Yu, Zhipeng Wu, Sijia Ding, Long Liu, Jingbo Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title | Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title_full | Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title_fullStr | Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title_full_unstemmed | Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title_short | Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2 |
title_sort | identification of lactoferrin-derived peptides as potential inhibitors against the main protease of sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537974/ https://www.ncbi.nlm.nih.gov/pubmed/34720187 http://dx.doi.org/10.1016/j.lwt.2021.112684 |
work_keys_str_mv | AT zhaowenzhu identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 AT lixin identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 AT yuzhipeng identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 AT wusijia identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 AT dinglong identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 AT liujingbo identificationoflactoferrinderivedpeptidesaspotentialinhibitorsagainstthemainproteaseofsarscov2 |